Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

Delivering small interfering RNA (siRNA) to tumors using clinically viable formulations remains the primary technical hurdle that prevents the development of siRNA therapy for cancer treatment. Over the past several years, significant effort has been devoted to explore novel delivery strategies, whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, L, Wang, R, Wilcox, D, Zhao, X, Song, J, Lin, X, Kohlbrenner, W M, Fesik, S W, Shen, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389750/
https://www.ncbi.nlm.nih.gov/pubmed/21956688
http://dx.doi.org/10.1038/gt.2011.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389750/
https://www.ncbi.nlm.nih.gov/pubmed/21956688
http://dx.doi.org/10.1038/gt.2011.146

Ejemplares similares